PROQR THERAPEUTICS N.V. news, videos and press releases
For more news please use our advanced search feature.
PROQR THERAPEUTICS N.V. - More news...
PROQR THERAPEUTICS N.V. - More news...
- ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
- ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
- ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
- ProQR Announces Year End 2023 Operating and Financial Results
- ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
- ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
- ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration
- ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
- ProQR Announces Third Quarter 2023 Operating and Financial Results
- ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing
- ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference
- ProQR Therapeutics Provides Update on Ophthalmic Assets
- ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference
- ProQR Announces Second Quarter 2023 Operating and Financial Results
- ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets
- ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit
- ProQR Announces First Quarter 2023 Operating and Financial Results
- ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023
- ProQR Announces Upcoming Investor Conferences in April and May
- ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023
- ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event
- ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing
- ProQR to Present at Upcoming Scientific and Industry Conferences
- ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023
- ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform
- Lilly and ProQR to Expand RNA Editing Collaboration
- Thinking about buying stock in Crown Electrokinetics, ThredUp, Icosavax, Engine Gaming and Media, or ProQR Therapeutics?
- ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022
- ProQR Announces Third Quarter 2022 Operating and Financial Results
- ProQR Announces Webcast of Presentation at the Upcoming Stifel 2022 Healthcare Conference